• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Impel Neuropharma secures $100 million for continued commercialization of Trudhesa nasal spray

Funds managed by Oaktree Capital Management will provide $100 million in funding to Impel NeuroPharma, with $50 million of that amount in cash up front as part of a royalty agreement on net sales of Trudhesa dihydroergotamine (DHE) nasal spray and the other $50 million in the form of a credit facility. The FDA approved Trudhesa for the treatment of migraine in September 2021.

Impel NeuroPharma Chairman and CEO Adrian Adams said, “This non-dilutive financing provides Impel with immediate and sufficient capital to support the continued successful launch and commercialization efforts for Trudhesa. Additionally, this transaction meets our objectives of strengthening our balance sheet, while retaining for our shareholders the majority of upside from growing Trudhesa sales.”

Oaktree Co-Portfolio Manager of Life Sciences Lending Aman Kumar commented, “We are very excited to form a long-term strategic partnership with Impel by supporting the ongoing commercialization of Trudhesa and development of additional therapies utilizing the company’s innovative drug delivery technology. There is a significant unmet medical need for targeted therapies within the upper nasal cavity and Oaktree believes that Trudhesa offers a highly differentiated and important offering to acute migraine patients, further validated by the impressive launch metrics to date.”

Read the Impel NeuroPharma press release.

Share

published on March 21, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews